On Assignment, Inc. — Q1 2015 Form 10-Q
Reporting period: Three months ended March 31, 2015; unaudited. The filing identifies the registrant as On Assignment, Inc., not Everforth Inc. The period’s results include the Physician Segment as discontinued operations following its sale on February 1, 2015.
Financial performance
| Metric | Q1 2015 | Q1 2014 |
|---|---|---|
| Revenue | $430.0 million | $406.9 million |
| Gross profit / margin | $135.9 million / 31.6% | $128.2 million / 31.5% |
| Operating income | $25.1 million | $26.5 million |
| Income from continuing operations | $13.0 million | $13.6 million |
| Net income | $39.1 million | $13.9 million |
| Diluted EPS | $0.75 | $0.25 |
| Net cash from (used in) operations | $19.9 million | ($4.3 million) |
Net income includes a $25.7 million after-tax gain on the Physician Segment sale; continuing-operations diluted EPS was $0.25 in both periods. Revenue grew 5.7% reported, or 6.7% on a constant-currency basis; foreign exchange reduced revenue by approximately $4.0 million. Operating margin was approximately 5.8%, versus 6.5% a year earlier. SG&A rose to $105.9 million, or 24.6% of revenue, from $96.1 million, or 23.6%.
Segment revenue: Apex $294.3 million, up 5.7%; Oxford $127.5 million, up 8.5%; Life Sciences Europe $8.3 million, down 24.3%. Apex and Oxford growth reflected higher average contract-professional counts. Direct-hire and conversion-fee revenue increased to $23.9 million from $19.0 million, supported by CyberCoders.
Cash, debt and liquidity
Cash and equivalents were $76.4 million at March 31, 2015, including $7.9 million held abroad that the company said it did not intend to repatriate. Working capital was $255.1 million. Operating cash flow was $19.9 million; investing cash flow was $106.9 million, principally reflecting $114.9 million in net sale proceeds; financing cash outflow was $81.5 million, including $80.6 million of debt principal payments.
Total debt declined to $334.6 million from $415.1 million at year-end 2014; the revolver had no borrowings and $121.8 million was available. The company reported a 1.77:1 leverage ratio against a 3.50:1 maximum covenant, stepping down to 3.25:1 beginning June 30, 2015. Weighted-average borrowing rate was 2.9%. Management said cash, revolver availability and expected operating cash flows should cover obligations, working capital and capital expenditures for the next 12 months.
Material changes, outlook and risks
- The Physician Segment was sold for $123.0 million; $6.0 million was held in escrow for 12 months. The company amended its credit facility so sale proceeds did not trigger mandatory debt prepayment.
- The $100 million share-repurchase authorization became effective February 23, 2015. The company repurchased 43,000 shares for $1.6 million during the quarter, leaving approximately $98.4 million authorized.
- Management cited seasonally weaker demand in the first and fourth quarters and higher first-quarter service costs from payroll-tax resets. No quantified earnings or revenue guidance was provided.
- Risks identified include demand for staffing services, economic conditions, attracting and retaining consultants and qualified professionals, competition, growth management, information systems, litigation, acquisition integration and strategic-plan execution. A 100-basis-point interest-rate change was estimated to affect annual interest expense by approximately $3.3 million. Ordinary-course legal matters were not expected by management to have a material effect; potential acquisition contingent consideration was approximately $11.0 million through 2015.
Key facts for investors to verify
- Confirm the issuer identity: the supplied filing is for On Assignment, Inc., although the request metadata names Everforth Inc.
- Assess continuing-business performance separately from the $25.7 million sale gain and discontinued operations.
- Track operating-margin pressure, SG&A growth, and Life Sciences Europe’s decline, including currency effects.
- Verify debt repayment, covenant headroom, revolver availability and any contingent consideration payments.
- Monitor whether sale escrow is released and whether the company uses the remaining share-repurchase authorization.